Skip to main content

Advertisement

SpringerLink
Log in

The management of subependymal giant cell tumors in tuberous sclerosis: a clinician's perspective

  • Review Paper
  • Published:
Child's Nervous System Aims and scope Submit manuscript

Abstract

Background

Tuberous sclerosis (TSC) is a genetic multisystem disorder associated with hamartomas in several organs including subependymal giant cell tumors (SGCT). SGCT have the potential to grow and therefore to become symptomatic and are one of the main causes of death in TSC individuals. Surgical resection is the procedure of choice for SGCT. However, the discovery of mTOR pathway upregulation in TSC-associated tumors and recent evidence that mTOR inhibitors may induce regression of SGCT open up new treatment strategies. Based on a review of the currently available literature and on personal experience, current options for the management of TSC patients and appropriate indications, taking into account benefits and risks of surgery and pharmacotherapy, are discussed.

Discussion

An earlier diagnosis of SGCT in neurologically asymptomatic children may allow a precocious surgical removal of the tumor, thus minimizing surgery-related morbidity and mortality. Biologically targeted pharmacotherapy with mTOR inhibitors such as sirolimus and everolimus provides a safe and efficacious treatment option for patients with SGCT and has the potential to change the clinical management of these tumors. However, whether pharmacotherapy is sufficient to control growth or if it only delays the need for surgical removal of symptomatic SGCT remains unclear. Further studies are needed to determine the optimal levels of mTOR inhibitors that preserve maximal anti-tumor efficacy while minimizing side effects.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Curatolo P, Bombardieri R, Jozwiak S (2008) Tuberous sclerosis. Lancet 372:657–668

    Article  PubMed  CAS  Google Scholar 

  2. DiMario FJ Jr (2004) Brain abnormalities in tuberous sclerosis complex. J Child Neurol 19:650–657

    PubMed  Google Scholar 

  3. Luat AF, Makki M, Chugani HT (2007) Neuroimaging in tuberous sclerosis complex. Curr Opin Neurol 20:142–150

    Article  PubMed  CAS  Google Scholar 

  4. Goh S, Butler W, Thiele EA (2004) Subependymal giant cell tumors in tuberous sclerosis complex. Neurology 63:1457–1461

    PubMed  Google Scholar 

  5. Adriaensen ME, Schaefer-Prokop CM, Stijnen T, Duyndam DA, Zonnenberg BA, Prokop M (2009) Prevalence of subependymal giant cell tumors in patients with tuberous sclerosis and a review of the literature. Eur J Neurol 16:691–696

    Article  PubMed  CAS  Google Scholar 

  6. Shepherd CW, Gomez MR, Lie JT, Crowson CS (1991) Causes of death in patients with tuberous sclerosis. Mayo Clin Proc 66:792–796

    PubMed  CAS  Google Scholar 

  7. Berhouma M (2010) Management of subependymal giant cell tumors in tuberous sclerosis complex: the neurosurgeon's perspective. World J Pediatr 6:103–110

    Article  PubMed  Google Scholar 

  8. Jiang T, Jia G, Ma Z, Luo S, Zhang Y (2011) The diagnosis and treatment of subependymal giant cell astrocytoma combined with tuberous sclerosis. Childs Nerv Syst 27:55–62

    Article  PubMed  Google Scholar 

  9. Franz DN, Leonard J, Tudor C, Chuck G, Care M, Sethuraman G, Dinopoulos A, Thomas G, Crone KR (2006) Rapamycin causes regression of astrocytomas in tuberous sclerosis complex. Ann Neurol 59:490–498

    Article  PubMed  CAS  Google Scholar 

  10. Koenig MK, Butler IJ, Northrup H (2008) Regression of subependymal giant cell astrocytoma with rapamycin in tuberous sclerosis complex. J Child Neurol 23:1238–1239

    Article  PubMed  Google Scholar 

  11. Krueger DA, Care MM, Holland K, Agricola K, Tudor C, Mangeshkar P, Wilson KA, Byars A, Sahmoud T, Franz DN (2010) Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med 363:1801–1811

    Article  PubMed  CAS  Google Scholar 

  12. Sepp T, Yates JR, Green AJ (1996) Loss of heterozygosity in tuberous sclerosis hamartomas. J Med Genet 33:962–964

    Article  PubMed  CAS  Google Scholar 

  13. Chan JA, Zhang H, Roberts PS, Jozwiak S, Wieslawa G, Lewin-Kowalik J, Kotulska K, Kwiatkowski DJ (2004) Pathogenesis of tuberous sclerosis subependymal giant cell astrocytomas: biallelic inactivation of TSC1 or TSC2 leads to mTOR activation. J Neuropathol Exp Neurol 63:1236–1242

    PubMed  CAS  Google Scholar 

  14. Ichikawa T, Wakisaka A, Daido S, Takao S, Tamiya T, Date I, Koizumi S, Niida Y (2005) A case of solitary subependymal giant cell astrocytoma: two somatic hits of TSC2 in the tumor, without evidence of somatic mosaicism. J Mol Diagn 7:544–549

    Article  PubMed  CAS  Google Scholar 

  15. Niida Y, Stemmer-Rachamimov AO, Logrip M, Tapon D, Perez R, Kwiatkowski DJ, Sims K, MacCollin M, Louis DN, Ramesh V (2001) Survey of somatic mutations in tuberous sclerosis complex (TSC) hamartomas suggests different genetic mechanisms for pathogenesis of TSC lesions. Am J Hum Genet 69:493–503

    Article  PubMed  CAS  Google Scholar 

  16. Jozwiak J, Jozwiak S, Wlodarski P (2008) Possible mechanisms of disease development in tuberous sclerosis. Lancet Oncol 9:73–79

    Article  PubMed  CAS  Google Scholar 

  17. Lopes MB, Altermatt HJ, Scheithauer BW, Shepherd CW, VandenBerg SR (1996) Immunohistochemical characterization of subependymal giant cell astrocytomas. Acta Neuropathol 91:368–375

    Article  PubMed  CAS  Google Scholar 

  18. Raju GP, Urion DK, Sahin M (2007) Neonatal subependymal giant cell astrocytoma: new case and review of literature. Pediatr Neurol 36:128–131

    Article  PubMed  Google Scholar 

  19. Medhkour A, Traul D, Husain M (2002) Neonatal subependymal giant cell astrocytoma. Pediatr Neurosurg 36:271–274

    Article  PubMed  Google Scholar 

  20. Mirkin LD, Ey EH, Chaparro M (1999) Congenital subependymal giant-cell astrocytoma: case report with prenatal ultrasonogram. Pediatr Radiol 29:776–780

    Article  PubMed  CAS  Google Scholar 

  21. Oikawa S, Sakamoto K, Kobayashi N (1994) A neonatal huge subependymal giant cell astrocytoma: case report. Neurosurgery 35:748–750

    Article  PubMed  CAS  Google Scholar 

  22. Tien RD, Hesselink JR, Duberg A (1990) Rare subependymal giant-cell astrocytoma in a neonate with tuberous sclerosis. AJNR Am J Neuroradiol 11:1251–1252

    PubMed  CAS  Google Scholar 

  23. Dabora SL, Jozwiak S, Franz DN, Roberts PS, Nieto A, Chung J, Choy YS, Reeve MP, Thiele E, Egelhoff JC, Kasprzyk-Obara J, Domanska-Pakiela D, Kwiatkowski DJ (2001) Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs. Am J Hum Genet 68:64–80

    Article  PubMed  CAS  Google Scholar 

  24. Pascual-Castroviejo I, Pascual-Pascual SI, Velazquez-Fragua R, Viano J, Carceller F, Hernandez-Moneo JL, Gutierrez-Molina M, Morales C (2010) Subependymal giant cell astrocytoma in tuberous sclerosis complex. A presentation of eight paediatric patients. Neurologia 25:314–321

    PubMed  CAS  Google Scholar 

  25. Frerebeau P, Benezech J, Segnarbieux F, Harbi H, Desy A, Marty-Double C (1985) Intraventricular tumors in tuberous sclerosis. Childs Nerv Syst 1:45–48

    Article  PubMed  CAS  Google Scholar 

  26. Fujiwara S, Takaki T, Hikita T, Nishio S (1989) Subependymal giant-cell astrocytoma associated with tuberous sclerosis. Do subependymal nodules grow? Childs Nerv Syst 5:43–44

    Article  PubMed  CAS  Google Scholar 

  27. Altermatt HJ, Scheithauer BW (1992) Cytomorphology of subependymal giant cell astrocytoma. Acta Cytol 36:171–175

    PubMed  CAS  Google Scholar 

  28. Torres VE, King BF, McKusick MA, Bjornsson J, Zincke H (2001) Update on tuberous sclerosis complex. Contrib Nephrol 136:33–49

    Article  PubMed  Google Scholar 

  29. Nabbout R, Santos M, Rolland Y, Delalande O, Dulac O, Chiron C (1999) Early diagnosis of subependymal giant cell astrocytoma in children with tuberous sclerosis. J Neurol Neurosurg Psychiatry 66:370–375

    Article  PubMed  CAS  Google Scholar 

  30. de Ribaupierre S, Dorfmuller G, Bulteau C, Fohlen M, Pinard JM, Chiron C, Delalande O (2007) Subependymal giant-cell astrocytomas in pediatric tuberous sclerosis disease: when should we operate? Neurosurgery 60:83–89, Discussion, 89–90

    PubMed  Google Scholar 

  31. Cuccia V, Zuccaro G, Sosa F, Monges J, Lubienieky F, Taratuto AL (2003) Subependymal giant cell astrocytoma in children with tuberous sclerosis. Childs Nerv Syst 19:232–243

    PubMed  Google Scholar 

  32. Genitori L, Donati PA, Giordano F, Mussa F, Sanzo M, Sardo L, Spacca B, Di Pietro G, Shamsaldin M, Oliveri G (2006) Neurosurgical strategies in the management of subependymal giant cell tumors in tuberous sclerosis complex. In: Curatolo P, Riva D (eds) Neurocutaneous syndromes in children. John Libbey Eurotext, Montrouge, France, pp 117–138

    Google Scholar 

  33. O'Callaghan FJ, Martyn CN, Renowden S, Noakes M, Presdee D, Osborne JP (2008) Subependymal nodules, giant cell astrocytomas and the tuberous sclerosis complex: a population-based study. Arch Dis Child 93:751–754

    Article  PubMed  Google Scholar 

  34. Di Rocco C, Iannelli A, Marchese E (1995) On the treatment of subependymal giant cell astrocytomas and associated hydrocephalus in tuberous sclerosis. Pediatr Neurosurg 23:115–121

    Article  PubMed  Google Scholar 

  35. Shepherd CW, Gomez MR (1991) Mortality in the Mayo Clinic Tuberous Sclerosis Complex Study. Ann NY Acad Sci 615:375–377

    Article  PubMed  CAS  Google Scholar 

  36. Hyman MH, Whittemore VH (2000) National Institutes of Health consensus conference: tuberous sclerosis complex. Arch Neurol 57:662–665

    Article  PubMed  CAS  Google Scholar 

  37. Roach ES, DiMario FJ, Kandt RS, Northrup H (1999) Tuberous Sclerosis Consensus Conference: recommendations for diagnostic evaluation. National Tuberous Sclerosis Association. J Child Neurol 14:401–407

    Article  PubMed  CAS  Google Scholar 

  38. Torres OA, Roach ES, Delgado MR, Sparagana SP, Sheffield E, Swift D, Bruce D (1998) Early diagnosis of subependymal giant cell astrocytoma in patients with tuberous sclerosis. J Child Neurol 13:173–177

    Article  PubMed  CAS  Google Scholar 

  39. Sinson G, Sutton LN, Yachnis AT, Duhaime AC, Schut L (1994) Subependymal giant cell astrocytomas in children. Pediatr Neurosurg 20:233–239

    Article  PubMed  CAS  Google Scholar 

  40. Kim SK, Wang KC, Cho BK, Jung HW, Lee YJ, Chung YS, Lee JY, Park SH, Kim YM, Choe G, Chi JG (2001) Biological behavior and tumorigenesis of subependymal giant cell astrocytomas. J Neurooncol 52:217–225

    Article  PubMed  CAS  Google Scholar 

  41. Franz DN, de Vries PJ, Crino PB (2009) Giant cell astrocytomas in tuberous sclerosis complex. Arch Dis Child 94:75–76

    PubMed  CAS  Google Scholar 

  42. Sharma MC, Ralte AM, Gaekwad S, Santosh V, Shankar SK, Sarkar C (2004) Subependymal giant cell astrocytoma–a clinicopathological study of 23 cases with special emphasis on histogenesis. Pathol Oncol Res 10:219–224

    Article  PubMed  Google Scholar 

  43. Pollizzi K, Malinowska-Kolodziej I, Stumm M, Lane H, Kwiatkowski D (2009) Equivalent benefit of mTORC1 blockade and combined PI3K-mTOR blockade in a mouse model of tuberous sclerosis. Mol Cancer 8:38

    Article  PubMed  Google Scholar 

  44. Meikle L, Pollizzi K, Egnor A, Kramvis I, Lane H, Sahin M, Kwiatkowski DJ (2008) Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: effects on mTORC1 and Akt signaling lead to improved survival and function. J Neurosci 28:5422–5432

    Article  PubMed  CAS  Google Scholar 

  45. Bissler JJ, McCormack FX, Young LR, Elwing JM, Chuck G, Leonard JM, Schmithorst VJ, Laor T, Brody AS, Bean J, Salisbury S, Franz DN (2008) Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med 358:140–151

    Article  PubMed  CAS  Google Scholar 

  46. Lam C, Bouffet E, Tabori U, Mabbott D, Taylor M, Bartels U (2010) Rapamycin (sirolimus) in tuberous sclerosis associated pediatric central nervous system tumors. Pediatr Blood Cancer 54:476–479

    Article  PubMed  Google Scholar 

  47. Birca A, Mercier C, Major P (2010) Rapamycin as an alternative to surgical treatment of subependymal giant cell astrocytomas in a patient with tuberous sclerosis complex. J Neurosurg Pediatr 6:381–384

    Article  PubMed  Google Scholar 

  48. Davies DM, Johnson SR, Tattersfield AE, Kingswood JC, Cox JA, McCartney DL, Doyle T, Elmslie F, Saggar A, de Vries PJ, Sampson JR (2008) Sirolimus therapy in tuberous sclerosis or sporadic lymphangioleiomyomatosis. N Engl J Med 358:200–203

    Article  PubMed  CAS  Google Scholar 

  49. Yalon M, Ben-Sira L, Constantini S, Toren A (2011) Regression of subependymal giant cell astrocytomas with RAD001 (Everolimus) in tuberous sclerosis complex. Childs Nerv Syst 27:179–181

    Article  PubMed  Google Scholar 

  50. Woodrum C, Nobil A, Dabora SL (2010) Comparison of three rapamycin dosing schedules in A/J Tsc2+/- mice and improved survival with angiogenesis inhibitor or asparaginase treatment in mice with subcutaneous tuberous sclerosis related tumors. J Transl Med 8:14

    Article  PubMed  Google Scholar 

  51. Lee N, Woodrum CL, Nobil AM, Rauktys AE, Messina MP, Dabora SL (2009) Rapamycin weekly maintenance dosing and the potential efficacy of combination sorafenib plus rapamycin but not atorvastatin or doxycycline in tuberous sclerosis preclinical models. BMC Pharmacol 9:8

    Article  PubMed  Google Scholar 

  52. Moavero R, Cerminara C, Curatolo P (2010) Epilepsy secondary to tuberous sclerosis: lessons learned and current challenges. Childs Nerv Syst 26:1495–1504

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Neuroscience Department, Pediatric Neurology Unit, Tor Vergata University of Rome, Rome, Italy

    Romina Moavero, Mariangela Pinci, Roberta Bombardieri & Paolo Curatolo

Authors
  1. Romina Moavero
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mariangela Pinci
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Roberta Bombardieri
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Paolo Curatolo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Paolo Curatolo.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Moavero, R., Pinci, M., Bombardieri, R. et al. The management of subependymal giant cell tumors in tuberous sclerosis: a clinician's perspective. Childs Nerv Syst 27, 1203–1210 (2011). https://doi.org/10.1007/s00381-011-1406-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00381-011-1406-0

Keywords

Search

Navigation